Ninlaro (ixazomib)
Multiple Myeloma
CommercialApproved
Key Facts
About Takeda Pharmaceutical
Founded in 1781, Takeda is a leading global biopharmaceutical company headquartered in Tokyo, Japan, with operations in over 80 countries. The company transformed through strategic acquisitions including Shire in 2019, building a diversified portfolio in oncology, rare diseases, neuroscience, and gastroenterology. Takeda focuses on developing breakthrough therapies while maintaining a strong commercial presence with blockbuster drugs generating billions in annual revenue.
View full company profileTherapeutic Areas
Other Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| Darzalex (daratumumab) | Johnson & Johnson | Approved |
| JNJ-4528 (CAR-T) | Johnson & Johnson | Phase 3 |
| Elrexfio | Pfizer | Approved |
| Revlimid (lenalidomide) | Bristol Myers Squibb | Commercial |
| Abecma (idecabtagene) | Bristol Myers Squibb | Commercial |
| Blenrep (belantamab mafodotin) | GSK plc | Approved |
| ABBV-383 | AbbVie | Phase 1/2 |
| REGN5458 | Regeneron Pharmaceuticals | Phase 1/2 |
| Tecvayli (teclistamab) | Genmab | Approved |
| Talquetamab | Genmab | Phase 3 |
| Lenalidomide (Generic Revlimid) | Dr. Reddy's Laboratories | Approved |
| YH29407 | Yuhan | Phase 1 |